Akston Biosciences files for IPO on NYSE American
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St rises as AI momentum holds heading into key earnings, Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailAkston Biosciences Corporation announced plans for an initial public offering of 2,222,222 shares of common stock. The company estimates the offering price will range between $8.00 and $10.00 per share.
The biotechnology company has applied to list its shares on the NYSE American under the ticker symbol "AXTN." The completion of the offering depends on meeting the exchange's listing standards.
ThinkEquity serves as the underwriter for the offering. No public market currently exists for Akston Biosciences' common stock prior to this IPO.
The announcement was made in a press release statement from the company.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ASM International posts Q3 net income of €308.1m, raises 2027 revenue target
- AstraZeneca may start work on cancer vaccines, CEO says
- Oracle adds AI agents and analytics tools to Fusion Data Intelligence
Create E-mail Alert Related Categories
Corporate News, IPOsRelated Entities
ThinkEquity, IPO, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
